On 3-4 May in Nairobi, Kenya, MSF gathered staff from our projects with experts from academia, clinical practice and the non-governmental sector to consider key issues in humanitarian paediatrics. These included:
Vaccination and vaccine-preventable diseases: Amid post-Covid-19 global setbacks in child vaccination coverage, sessions spotlighted recent increases in vaccine-preventable disease outbreaks, potential new vaccination strategies and emergency responses, and MSF’s role in vaccine advocacy and catch-up campaigns.
Nutrition: Talks covered the nexus of nutrition with other key conference topics, the latest malnutrition guidance and tools, and MSF’s priorities in nutritional care.
Paediatric HIV: With half of all HIV-positive children globally not receiving antiretroviral therapy, presenters reviewed the latest paediatric testing/treatment recommendations and discussed barriers and potential solutions to implementation, nutritional challenges in children with HIV, and systems strengthening for preventing and monitoring paediatric HIV.
Click below to read the abstracts. And stay tuned for more conference content, coming soon.
Complex humanitarian emergencies and other low-resource settings can be exceedingly difficult places to provide quality mental health (MH) care. Yet these environments also often have a high burden of mental health care needs.
This collection presents a set of articles describing how MSF teams have adapted and evaluated ways of bringing clinically impactful MH care to neglected communities and patients—from forcibly displaced populations in northern Nigeria to Syrian refugees in Lebanon and typhoon survivors in the Philippines. It also highlights work on developing new tools for providing clinical supervision and for identifying those patients most in need of care in fragile settings, and on new approaches to delivering MH services during the Covid-19 pandemic.
Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N, et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A, et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Mesic A, Ishaq S, Khan WH, Mureed A, Mar HT, et al.
2022-01-03 • Tropical Medicine and International Health
2022-01-03 • Tropical Medicine and International Health
OBJECTIVES To describe the effect of adaptations to a person-centred care with short oral regimens on retention in care for rifampicin-resistant TB (RR-TB) in Kandahar province, Afgh...
Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L
2021-05-29 • Trials
2021-05-29 • Trials
When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and availabl...
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION Almost 500,000 people worldwide develop multidrug-resistant tuberculosis (MDR-TB) annually, with a treatment success rate of around 60%. Current treatment consists of up...
Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M, et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...